



Myriad Genetics Fiscal Fourth-Quarter 2016 Earnings Call

08/09/2016



Forward Looking Statements

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

For additional information on GAAP to non-GAAP reconciliation see:
<https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/>

Non-GAAP Financial Measures

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

	Fiscal Year 2017
GAAP diluted earnings per share	\$0.47 - \$0.57
Acquisition – amortization of intangible assets	\$0.36
Acquisition – one time charges	\$0.17
Non-GAAP diluted earnings per share	\$1.00 - \$1.10



Fiscal Year 2016 Financial Results

FY16 Actual Results

YoY Growth

Revenue

\$753.8M

4%

Adjusted EPS

\$1.63


12%

GAAP EPS

\$1.71

58%


Hereditary Cancer Revenue Remains Relatively Stable



Substantial Progress With Key Pipeline Products

Test	Volume	YoY Volume Growth	New Private Payer Lives
 Polaris	15,300	94%	29M
 Vectra [®] DA disease activity test	160,000	11%	3M

Extensive Collaborations With >22 PARP Clinical Studies



*Includes U.S., Canada and EU6

Advancing Key Tests Toward Market Adoption

Total Addressable Market (TAM)		\$10B+	\$10B+	\$15B	\$5B
Product		Stage 1 DISCOVERY	Stage 2 VALIDATION	Stage 3 REIMBURSEMENT	Stage 4 ADOPTION
Oncology	myRisk® Hereditary Cancer				
	BRACAnalysis CDx™ (Tumor)				
	EndoPredict®				
	myChoice™ HRD				
	myPlan® Lung Cancer				
Preventive Care	myRisk® Hereditary Cancer				
	GeneSight® Psychotropic				
	myPath® Bipolar				
	myPath® Endometriosis				
Urology	Prolaris®				
	myPlan® Renal				
Auto- Immune	Vectra DA®				
	myPath® Psoriatic Arthritis				
Derm.	myPath® Melanoma				
	myPath® Psoriatic Arthritis				
Neuro.	GeneSight® Psychotropic				
	myPath® Bipolar				

Two Acquisitions Additive To Five Year Plan



- Global leader in genetic testing for drug selection in mental health market
- Core product is GeneSight®, which provides individualized treatment recommendations on 55 antidepressant, antipsychotic, and other mental health medications
- Currently call primarily on psychiatrists in the United States
- Testing services provided from Assurex's CLIA laboratory in Mason, Ohio

Amount To Be Paid:
\$225M upfront
\$185M in milestones
Total Addressable
Market = >\$18B



- European kit manufacturer of high value diagnostics
- Core product is EndoPredict a breast cancer prognostic test
- Brings to Myriad substantial kit manufacturing and development expertise
- Myriad is the current exclusive distributor of EndoPredict in all countries except the U.S. and China

Amount Paid:
€35M upfront
€15M in milestones
Total Addressable
Market = >\$600M



Fiscal Fourth-Quarter 2016 Revenue By Product

(in millions)

Product	4Q16	4Q15	YoY Growth
Hereditary Cancer	\$152.8	\$163.8	(7%)
Vectra DA	\$12.7	\$11.8	8%
Polaris	\$3.5	\$0.7	400%
Other	\$4.8	\$2.5	92%
Total Molecular Diagnostic Revenue	\$173.8	\$178.8	(3%)
Pharmaceutical & Clinical Services	\$12.7	\$11.1	14%
Total Revenue	\$186.5	\$189.9	(2%)

Fiscal Fourth-Quarter Financial Results

(in millions except per share data)	4Q16	4Q15	YoY Growth
Total Revenue	\$186.5	\$189.9	(2%)
Gross Profit	\$146.5	\$152.4	(4%)
Gross Margin	78.6%	80.3%	NA
Operating Income	\$35.7	\$36.2	(1%)
Adjusted Operating Income	\$38.9	\$48.2	(19%)
Adjusted Operating Margin	20.9%	25.4%	NA
Net Income	\$23.4	\$18.7	25%
Diluted EPS	\$0.32	\$0.26	23%
Adjusted EPS	\$0.36	\$0.41	(12%)




1Q17 and FY17 Financial Guidance

Metric	Fiscal First-Quarter 2017	Fiscal Year 2017
Revenue	\$168 to \$170 million	\$740 to \$760 million
Diluted EPS	\$0.14 to \$0.16	\$0.47 to \$0.57
Adjusted EPS	\$0.25 to \$0.27	\$1.00 to \$1.10

For additional information on GAAP to non-GAAP reconciliation see: <https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/>

Hereditary Cancer Has Been Stable for Last 10 Quarters



Guidance Assumptions for FY17

Potential Downsides

- 1) Hereditary cancer out of network decisions

Base Case

- 1) Hereditary cancer decrease consistent with Q4 FY16 YoY decline
- 2) No incremental payer coverage for Vectra DA, GeneSight, Prolaris or EndoPredict
- 3) No revenue from myPath, myPlan Lung Cancer or myChoice HRD
- 4) No U.S. EndoPredict revenue
- 5) FY17 pharma & clinical services revenue < FY16
- 6) Three quarters of Assurex Health revenue

Potential Upsides


- 1) Hereditary cancer oncology share stabilizes
- 2) New hereditary cancer indications provide growth
- 3) Additional private payer or Medicare coverage for Vectra DA, Prolaris or GeneSight
- 4) Primary care indication for GeneSight
- 5) Revenue from myPath Melanoma, myPlan Lung Cancer or myChoice HRD
- 6) UK, Canadian or German reimbursement for EndoPredict

Market Expansion Opportunity in Hereditary Cancer Exceeds \$1B Annually


Indication		Added Market Potential	Guidelines	Contracting
	Colon Cancer @ 5% Mutation Risk	+\$100M	✓	53%
	All Endometrial Cancer	+\$150M	✓	53%
	Breast Cancer <60 years	+\$150M	FY17	FY18
	All Pancreatic Cancer	+\$125M	Partial	FY17
	Prostate Cancer	+\$120M	Partial	FY17
	Colon Cancer Asymptomatic Market	+ \$18B (6M patients)	✓	53%

Two Improvements to myRisk Hereditary Cancer Test


1. Updating gene content to provide better care



2. Offering customizable format for customers



PROMPT Study Show Discordance Between Hereditary Cancer Laboratories




Source: PROMPT Study presented at ASCO 2016 Annual Meeting

Copyright © 2016 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

New Product Pipeline Market Opportunity

> \$1B Reimbursed TAM




Currently Reimbursed Market Opportunity


Total Market Opportunity

Three New Commercial Contracts for Vectra DA and Prolaris

U.S. Vectra DA Insurance Coverage (42%)



U.S. Prolaris Insurance Coverage (36%)





EndoPredict Most Often Correct When Test Result Disagrees With Oncotype Dx

Oncotype DX[®]


Rate of 10-year Distant Metastases		
Non-Low	10.2%	29.9%
Low	4.6%	26.9%
	Low	High

EndoPredict[®]

*Data presented at San Antonio Breast Cancer Symposium in 2015 from the TransATAC cohort
Oncotype Dx is a registered trademark of Genomic Health Inc.

GeneSight Is One of the Fastest Growing New Diagnostic Tests in History

Less than 5% market penetration to date




Source: Company data; Wells Fargo Securities, LLC estimates

Oncotype Dx is a registered trademark of Genomic Health Inc., FoundationOne is a trademark of Foundation Medicine Inc., Afirma is a trademark of Veracyte Inc.

Most Major Depressive Disorder Patients are Seen in Primary Care

TREATING PHYSICIAN FOR PATIENTS WITH MDD




- 13,600 High Volume Psychiatrists
- Other 35,000 Psychiatrists
- Other
- >200,000 Primary Care and Other
- 16,000 High Volume Primary Care

- Significant shortage of psychiatrists in U.S. and getting worse
- Most MDD patients are seen by primary care consisting of general practice, internal medicine, and OBGYNs
- Top 16,000 primary care physicians and OBGYN channel order almost half of the prescriptions for MDD
- ≈half of prescriptions ordered by 30,000 psychiatrists and primary care doctors




Niraparib Highly Efficacious in Both myChoice HRD+ Patients and Germline BRCA+ Patients

Progression Free Survival




Extensive Collaborations With >22 PARP Clinical Studies




*Includes U.S., Canada and EU6

Completing myPath Melanoma Reimbursement Dossier


myPath Melanoma Diagnostic Accuracy




myPath Melanoma Clinical Utility



Building Towards >\$600M Global Market for EndoPredict



Incremental Revenue With Broad Reimbursement



Fully reimbursed at FY16 volume levels, Prolaris, Vectra DA, and GeneSight would drive > \$300M in incremental revenue and > \$2.00 per share in incremental earnings power

Advancing Key Tests Toward Market Adoption

Total Addressable Market (TAM)		\$10B+	\$10B+	\$15B	\$5B
Product		Stage 1 DISCOVERY	Stage 2 VALIDATION	Stage 3 REIMBURSEMENT	Stage 4 ADOPTION
Oncology	myRisk® Hereditary Cancer				
	BRACAnalysis CDx™ (Tumor)				
	EndoPredict®				
	myChoice™ HRD				
	myPlan® Lung Cancer				
Preventive Care	myRisk® Hereditary Cancer				
	GeneSight® Psychotropic				
	myPath® Bipolar				
	myPath® Endometriosis				
Urology	Prolaris®				
	myPlan® Renal				
Auto- Immune	Vectra DA®				
	myPath® Psoriatic Arthritis				
Derm.	myPath® Melanoma				
	myPath® Psoriatic Arthritis				
Neuro.	GeneSight® Psychotropic				
	myPath® Bipolar				